Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic Biomarkers Offer New Hope In Identifying Prostate Cancer

Executive Summary

Although physicians still struggle with the best ways to treat patients suspected of having prostate cancer, a new group of genetic-based tests could provide new tools that will help improve diagnostic accuracy. These new biomarkers offer hope in reducing the number of patients who receive unnecessary treatment for cancers that are not actually present in their bodies and for those cancers not aggressive enough to cause harm.

Advertisement

Related Content

Prostate Cancer: Dissatisfaction With Current Diagnostics Drives Interest In Innovation

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel